T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity

Component: Nanoparticle Core; Description: PLGA (poly(lactic-co-glycolic acid), 50:50, 10-15 kDa, acid end-capped) — FDA-approved biodegradable polymer

Component: Surface PEGylation; Description: Mal-PEG-PLGA (5-10 kDa) — 25% w/w blend; provides maleimide groups for antibody conjugation and stealth properties

Component: Targeting Moieties; Description: F(ab')₂ fragments (not full IgG) — generated by IdeS/IdeZ cleavage to remove Fc and prevent Fc receptor-mediated clearance

Component: Targets Tested; Description: • CD8a (YTS169.4) — lineage marker<br>• PD-1 (clone 332.6D2; murine; pembrolizumab for human)<br>• GITR (DTA-1)<br>• Gr-1 (RB6-8C5)

Component: Conjugation Chemistry; Description: Maleimide-thiol coupling: F(ab')₂ reduced with 0.5 mM DTT to expose sulfhydryl groups; conjugated to Mal-PEG-PLGA; 25 μg antibody/mg polymer

Component: Nanoparticle Properties; Description: • Size: ~270 nm (uncoated: 267 ± 8 nm; CD8 NP: 273 ± 8 nm; Iso NP: 269 ± 8 nm)<br>• Zeta potential: varied by payload<br>• Drug loading: SD-208: 20 μg/mg polymer; R848: not specified

Component: Payloads; Description: • SD-208 — TGFβRI kinase inhibitor (poorly water-soluble; immunosuppression blockade)<br>• R848 (resiquimod) — TLR7/8 agonist (innate immune stimulation)

Component: Fluorescent Tracers; Description: DiD (for flow cytometry tracking)

Parameter: In Vitro Binding; Details: CD8+ T cells enriched from murine spleens; nanoparticles (DiD-loaded) incubated 30 min at 37°C; flow cytometry; OT-I T cells activated with B16-OVA or CD3/CD28 beads

Parameter: Human T Cell Studies; Details: PBMCs from healthy donors; activated with anti-CD3/CD28 (ImmunoCult); pembrolizumab F(ab')₂ nanoparticles; binding assessed by flow cytometry; competition with free pembrolizumab

Parameter: In Vivo Binding (CD8); Details: C57BL/6; B16 melanoma s.c. (~400 mm³); DiD-loaded nanoparticles i.v.; harvest at 1, 24, 48 h; flow cytometry of blood, spleen, tumour, TdLN

Parameter: In Vivo Binding (PD-1); Details: B16 melanoma (~400 mm³); PD-1-targeting nanoparticles i.v.; harvest at 1 h; flow cytometry of tumour T cells

Parameter: Therapeutic Study (SD-208); Details: MC38 s.c. (day 0); treatment days 5-23 (every other day ×10); 2 mg NPs = 20 μg anti-PD-1 + 40 μg SD-208; tumour volume and survival

Parameter: R848 Recruitment Study; Details: MC38 or B16 s.c. (day 0); single i.v. injection day 14 (2 mg NPs = 20 μg anti-PD-1 + 60 μg R848); harvest at 72 h; IHC for CD8; ImageJ quantification

Parameter: R848 + Anti-PD-1 Sensitisation; Details: MC38 s.c.; R848 NPs (PD-1-targeted or untargeted) days 5,7,9; anti-PD-1 (200 μg, i.p.) days 11,14,17; tumour volume/survival

Parameter: Controls; Details: Isotype F(ab')₂ NPs; free SD-208; free R848 + anti-PD-1 IgG; untargeted R848 NPs + anti-PD-1 IgG; no treatment; blank NPs

Parameter: Sample Sizes; Details: Binding: n=3-6; Therapy: n=6-8; IHC: n=5 (10 fields/mouse)

Parameter: Statistical Tests; Details: Two-tailed Student's t-test; one-way ANOVA with Tukey's post hoc; log-rank (Mantel-Cox) for survival

Analysis Category: Nanoparticle Characterisation; Methods: DLS (size, zeta potential); SEM (morphology); BCA assay (antibody quantification); UV-Vis absorbance (drug loading/release)

Analysis Category: Antibody Cleavage/Conjugation; Methods: IdeS/IdeZ cleavage; non-reducing SDS-PAGE; Western blot (Fab-specific, Fc-specific); DTT reduction

Analysis Category: Flow Cytometry; Methods: BD LSR Fortessa; murine antibodies: CD8a, CD8b, CD4, CD3e, PD-1, GITR, CD44, CD62L, CD11b, F4/80, Gr-1, NK1.1, granzyme B, IFNγ; human: PD-1, CD3; Zombie Aqua live/dead

Analysis Category: T Cell Proliferation; Methods: CFSE or CellTrace Violet dilution; anti-CD3/CD28 beads (1:2); TGFβ1 (2 ng/mL) ± SD-208 (1 μM)

Analysis Category: Cytokine Detection; Methods: ELISA: IFNγ (BioLegend); granzyme B intracellular staining (flow cytometry)

Analysis Category: Immunohistochemistry; Methods: CD8 staining (clone 4SM15; DAB or red chromagen); 10 random fields/mouse; ImageJ quantification; MC38 and B16 tumours

Analysis Category: Drug Release; Methods: PBS + 10% serum; absorbance at 370 nm (SD-208) or 280 nm (R848)

Analysis Category: Western Blot; Methods: Fab-specific (1:20,000) and Fc-specific (1:5,000) secondary antibodies

Parameter: Size (nm); Uncoated NPs: 267 ± 8; Isotype NPs: 269 ± 8; CD8a NPs: 273 ± 8

Parameter: Antibody conjugation; Uncoated NPs: -; Isotype NPs: Yes (cleaved); CD8a NPs: Yes (cleaved)

Parameter: Fc detection; Uncoated NPs: -; Isotype NPs: None; CD8a NPs: None

Parameter: Drug loading (SD-208); Uncoated NPs: -; Isotype NPs: 20 μg/mg polymer; CD8a NPs: 20 μg/mg polymer

Target: CD8a; Cell Type: Murine CD8+ T cells; % Binding (High NP Dose): ~90%; Isotype Control: <10%

Target: PD-1 (murine); Cell Type: Activated OT-I T cells; % Binding (High NP Dose): Dose-dependent; Isotype Control: Overlaid with isotype

Target: PD-1 (human); Cell Type: Activated human T cells; % Binding (High NP Dose): ~40% (DiD+); Isotype Control: Significantly lower

Target: GITR; Cell Type: Tumour CD4+ T cells (in vivo); % Binding (High NP Dose): Specific binding; Isotype Control: Minimal

Tissue: Blood; % CD8+ T Cells Bound: ~90-100%; % CD3+CD8- Bound: Minimal

Tissue: Spleen; % CD8+ T Cells Bound: ~90-100%; % CD3+CD8- Bound: Minimal

Tissue: Tumour; % CD8+ T Cells Bound: ~90-100%; % CD3+CD8- Bound: Minimal

Tissue: Persistence; % CD8+ T Cells Bound: ≥48 h (decreasing over time); % CD3+CD8- Bound: -

Tissue: TdLN accumulation; % CD8+ T Cells Bound: Increases over 48 h; % CD3+CD8- Bound: -

Tissue: CD8+ T cell depletion; % CD8+ T Cells Bound: None (vs. free anti-CD8 IgG); % CD3+CD8- Bound: -

Parameter: % DiD+ of PD-1+ T cells; Isotype NPs: ~1.5%; PD-1 NPs: ~5%; Fold Increase: ~3×

Parameter: Blood PD-1+ T cells; Isotype NPs: Low; PD-1 NPs: >10× increase; Fold Increase: >10×

Parameter: PD-1 expression (day 3); Result: ~60% of T cells

Parameter: Dose-dependent binding; Result: Yes

Parameter: Competition with free pembrolizumab; Result: Significant blockade (p < 0.05)

Parameter: Internalisation; Result: ~50% of NPs internalised by 72 h

Parameter: T cell proliferation (CFSE dilution); +TGFβ (2 ng/mL): Inhibited; Free SD-208: Restored; SD-208 NPs: Restored

Parameter: Granzyme B expression; +TGFβ (2 ng/mL): Low; Free SD-208: Restored; SD-208 NPs: Restored

Parameter: IFNγ secretion; +TGFβ (2 ng/mL): Low; Free SD-208: Restored; SD-208 NPs: Restored

Treatment: No treatment; Tumour Growth: Rapid; Median Survival: ~26 days; Significance: -

Treatment: Full-length anti-PD-1 + free SD-208; Tumour Growth: Modest delay; Median Survival: ~31 days; Significance: NS

Treatment: Full-length anti-PD-1 + Iso SD-208 NPs; Tumour Growth: Modest delay; Median Survival: ~31 days; Significance: NS

Treatment: Anti-PD-1 SD-208 NPs; Tumour Growth: Significant delay; Median Survival: ~33 days; Significance: p < 0.001

Tumour Model: MC38; PBS: Low; Free anti-PD-1 + R848: No increase; Untargeted R848 NPs: No increase; PD-1-Targeted R848 NPs: Significant increase

Tumour Model: B16; PBS: Low; Free anti-PD-1 + R848: No increase; Untargeted R848 NPs: No increase; PD-1-Targeted R848 NPs: Significant increase

Tumour Model: CD8+ T cell infiltration; PBS: Baseline; Free anti-PD-1 + R848: Baseline; Untargeted R848 NPs: Baseline; PD-1-Targeted R848 NPs: Only targeted delivery works

Treatment: Untargeted R848 NPs + anti-PD-1; Tumour Growth Delay: Modest; Survival Benefit: Modest

Treatment: PD-1-Targeted R848 NPs + anti-PD-1; Tumour Growth Delay: Significant; Survival Benefit: Significant

Treatment: Mechanism; Tumour Growth Delay: Targeted R848 primes tumour; Survival Benefit: Improves response to checkpoint blockade

Parameter: Target; Result: GITR on CD4+ T cells in B16 tumours

Parameter: Binding; Result: Specific and robust

Parameter: Platform modularity; Result: Confirmed

1. Modest survival benefit: SD-208 delivery extended median survival from ~26 days to ~33 days—statistically significant but modest. The authors note that "more favourable survival outcomes might be achieved in a tumour with more CD8+ TILs or upon administration of a different payload."

2. No significant tumour regression: The SD-208 study showed delayed growth but not tumour rejection; no complete responses were reported.

3. R848 effect in B16 modest: While R848 recruited CD8+ T cells, the absolute increase in the poorly immunogenic B16 model was modest and required combination with anti-PD-1.

4. No combination with other immunotherapies tested: The study tested SD-208 with anti-PD-1 (which was also the targeting antibody), but did not test combinations with other checkpoint inhibitors (anti-CTLA-4, anti-LAG-3) or additional immunomodulators.

5. NP size relatively large: ~270 nm particles may have limited diffusion in tumours; the authors acknowledge that "nanoparticles carrying cytotoxic payloads experience impaired diffusion into tumours."

6. Mechanism of action incompletely defined: For R848, the authors propose local activation of plasmacytoid DCs as the mechanism, but this was not experimentally confirmed.

7. No pharmacodynamic biomarkers: The study did not measure drug levels in tumours, T cell activation markers in vivo, or changes in the tumour microenvironment beyond CD8+ IHC.

8. TGFβ pathway complexity: TGFβ has pleiotropic effects; inhibiting it may affect both immune cells and tumour cells. The authors note that "inhibition of TGFβR1 did not lead to curative outcomes under the conditions examined."

9. Human translation uncertainty: While pembrolizumab-derived nanoparticles bound to human T cells, the human studies were limited to in vitro binding; no humanized mouse models or ex vivo functional assays were performed.

10. Potential off-target effects on other PD-1+ cells: PD-1 is expressed on other immune cells (e.g., Tregs, B cells, some myeloid cells); targeting may affect these populations.

11. No dosing optimisation: A single dose regimen was used; optimal dose, schedule, and release kinetics were not systematically evaluated.

12. Limited understanding of NP fate: While binding was confirmed, the fraction of NPs that reach the tumour versus those cleared by the MPS was not quantified.

Report prepared based on the published Nature Communications article. For full experimental details, supplementary figures, and complete references, please refer to the original publication.